Drug intelligence / Profile preview

FREE-004

Development stage: Unknown
Lead developer: Freedom Biosciences
Modality: Small Molecules

Overview

FREE-004 is an undisclosed neuropsychiatric drug candidate being developed by Freedom Biosciences (Freedom Ventures). It is part of a pipeline focused on next-generation mental health treatments, which typically involve ketamine-based combination therapies or 5-HT2A receptor modulators. While specific details regarding its mechanism of action and primary indication remain proprietary, the candidate was projected to enter Phase 1 clinical trials in 2024 and progress to Phase 2 by 2026. The program aims to address unmet needs in neuropsychiatric conditions, potentially including treatment-resistant depression or substance use disorders.

Beyond the preview

Go deeper on FREE-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FREE-004.

Explore the full profile